This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Methods used to judge relevance and validity, and for extracting data
Quality was assessed by one reviewer and checked by a second reviewer, with any differences being resolved by consensus.
Number of primary studies included
Thirty-three RCTs were used to assess clinical effectiveness.
Methods of combining primary studies
The authors stated that a meta analysis was not undertaken because of the diversity of the interventions and comparators. Also, because of differences in or insufficient detail on the outcomes used, patient characteristics, and drug dose and administration. A narrative method was used instead. In the economic model, median survival by regimen was aggregated using the number of patients as the weight.
Investigation of differences between primary studies
The differences among the RCTs were discussed in the narrative, although it was not suggested how these differences affected the estimate of the effectiveness of the technology. The results for each RCT, along with 95% confidence intervals and p-values were tabulated in the original paper. The length of follow-up in the trials was not stated
Measure of benefits used in the economic analysis
The outcome measure used was life-years saved
Direct costs
The costs were those incurred by the hospital in order to provide the treatment. It was not stated how long the treatments lasted, only that each treatment required 3 or 4 cycles. Discounting was not applied to the costs. The resource use and the unit costs were not described in detail, and were not reported separately. The costs of the treatments were estimated from published and unpublished data. The costs of BSC were estimated by analysing the case notes from 36 patients with lung cancer. The authors stated that the costs of inpatient care, outpatient care, home visits and treatment costs were included, but provided no further details. The costs were reported as average and incremental (relative to BSC only).
Statistical analysis of costs
The costs were not treated stochastically.
Indirect Costs
The indirect costs were not included.
Currency

UK pounds sterling ().
Sensitivity analysis
One-way sensitivity analyses were carried out using a wide range of parameters. These included: the number of cycles of treatment per drug regimen;
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an increase in the price of anti-emetics; and the best and worst median survival time used in the trials
Estimated benefits used in the economic analysis
The incremental benefits, as median survival in months, were reported in the 'Results of the Review' section. The study converted these to the expected gain in life-years saved, by dividing these results by twelve. The side effects of treatment were not considered in the measurement of the economic benefit.
The study did not provide sufficient detail for the reader to understand how the estimates of costs were calculated. Some one-way sensitivity analyses were conducted, by reducing the price of the drugs, increasing the price of antiemetics, and changing the cost of BSC.
The authors considered that the costs of routine care would be much lower than those derived using data from trials. This is because in routine care, physicians would review continuation on a course by course basis and discontinue treatment for patients who were not responding. A major flaw was that the incremental analysis was incorrectly performed. BSC was used as the comparator for all other technologies. However, it is clear that several technologies would have been dominated (higher cost and lower effectiveness). These include those using GEM. In fact, the authors cite GEM as the most cost-effective. Once dominated technologies have been eliminated, the VIN technologies would have the lowest cost increase per gain in life-years. The PAX 135 and 250 mg/m2 technologies would be more effective, but at a higher increase in cost.
Other issues
The authors claimed that VIN and GEM as single and combination therapies, and PAX as combination therapy, are costeffective. However, they did not make any explicit statement about the cost-effectiveness ceiling ratio that was applied in order to make these judgements, although it appears from the data to have been less than 30,000 per life-year saved.
The sensitivity analyses were limited to univariate analysis. The analyses based on reducing the number of cycles of treatment assumed that this did not affect the effectiveness in terms of survival.
